{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T13:54:59Z","timestamp":1791035699671,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bpgastro.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Gastroenterology"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.bpg.2013.01.001","type":"journal-article","created":{"date-parts":[[2013,4,10]],"date-time":"2013-04-10T14:01:29Z","timestamp":1365602489000},"page":"833-841","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Biotherapies for GEP-NETs"],"prefix":"10.1016","volume":"26","author":[{"given":"Kjell","family":"\u00d6berg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.bpg.2013.01.001_bib1","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \"carcinoid\": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bpg.2013.01.001_bib2","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1210\/er.2003-0014","article-title":"The diagnosis and medical management of advanced neuroendocrine tumors","volume":"25","author":"Kaltsas","year":"2004","journal-title":"Endocr Rev"},{"key":"10.1016\/j.bpg.2013.01.001_bib3","series-title":"WHO classification of tumours of the digestive system","first-page":"13","article-title":"Nomenclature and classification of neuroendocrine neoplasms of the digestive system","author":"Rindi","year":"2010"},{"issue":"2","key":"10.1016\/j.bpg.2013.01.001_bib4","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000182196","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification","volume":"90","author":"Kloppel","year":"2009","journal-title":"Neuroendocrinology"},{"issue":"Suppl 2","key":"10.1016\/j.bpg.2013.01.001_bib5","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1093\/annonc\/12.suppl_2.S31","article-title":"Somatostatin receptor subtype expression in human tumors","volume":"12","author":"Hofland","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bpg.2013.01.001_bib6","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0921-4410(03)21025-5","article-title":"Neuroendocrine tumors \u2013 somatostatin receptor expression and somatostatin analog treatment","volume":"21","author":"Janson","year":"2003","journal-title":"Cancer Chemother Biol Response Modif"},{"issue":"7","key":"10.1016\/j.bpg.2013.01.001_bib7","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1007\/s002590100541","article-title":"Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands","volume":"28","author":"Reubi","year":"2001","journal-title":"Eur J Nucl Med"},{"issue":"10","key":"10.1016\/j.bpg.2013.01.001_bib8","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1210\/jcem.83.10.5314","article-title":"Immunohistochemical localization of somatostatin receptor sst2A in human pancreatic islets","volume":"83","author":"Reubi","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.bpg.2013.01.001_bib9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/frne.1999.0183","article-title":"Somatostatin and its receptor family","volume":"20","author":"Patel","year":"1999","journal-title":"Front Neuroendocrinol"},{"issue":"4","key":"10.1016\/j.bpg.2013.01.001_bib10","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1172\/JCI119225","article-title":"Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation","volume":"99","author":"Shimon","year":"1997","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.bpg.2013.01.001_bib11","first-page":"140","article-title":"Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas","volume":"86","author":"Saveanu","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.bpg.2013.01.001_bib12","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/nrd1255","article-title":"Opportunities in somatostatin research: biological, chemical and therapeutic aspects","volume":"2","author":"Weckbecker","year":"2003","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10.1016\/j.bpg.2013.01.001_bib13","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1586\/era.09.26","article-title":"Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors","volume":"9","author":"Oberg","year":"2009","journal-title":"Expert Rev Anticancer Ther"},{"issue":"68","key":"10.1016\/j.bpg.2013.01.001_bib14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.179.4068.77","article-title":"Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone","volume":"179","author":"Brazeau","year":"1973","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.bpg.2013.01.001_bib15","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/0024-3205(82)90087-X","article-title":"SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action","volume":"31","author":"Bauer","year":"1982","journal-title":"Life Sci"},{"issue":"11 Suppl International","key":"10.1016\/j.bpg.2013.01.001_bib16","first-page":"1","article-title":"The history of somatostatin analogs","volume":"28","author":"Pless","year":"2005","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"10.1016\/j.bpg.2013.01.001_bib17","first-page":"18","article-title":"Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide","volume":"82","author":"Caron","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.bpg.2013.01.001_bib18","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1073\/pnas.83.6.1896","article-title":"Synthesis and biological activity of highly potent octapeptide analogs of somatostatin","volume":"83","author":"Cai","year":"1986","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.bpg.2013.01.001_bib19","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1530\/eje.0.1460707","article-title":"SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile","volume":"146","author":"Bruns","year":"2002","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.bpg.2013.01.001_bib20","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1136\/gut.38.3.430","article-title":"Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours","volume":"38","author":"Arnold","year":"1996","journal-title":"Gut"},{"issue":"Suppl 2","key":"10.1016\/j.bpg.2013.01.001_bib21","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1093\/annonc\/10.suppl_2.S31","article-title":"Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook","volume":"10","author":"Eriksson","year":"1999","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.bpg.2013.01.001_bib22","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1046\/j.1365-2036.2000.00738.x","article-title":"Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR","volume":"14","author":"Tomassetti","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.bpg.2013.01.001_bib23","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S0889-8553(21)00447-7","article-title":"The use of the long-acting somatostatin analogue, octreotide acetate, in patients with islet cell tumors","volume":"18","author":"Maton","year":"1989","journal-title":"Gastroenterol Clin North Am"},{"issue":"3","key":"10.1016\/j.bpg.2013.01.001_bib24","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/annonc\/mdj113","article-title":"Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma","volume":"17","author":"Panzuto","year":"2006","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.bpg.2013.01.001_bib25","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0889-8529(18)30381-5","article-title":"Medical therapy of VIPomas","volume":"18","author":"O'Dorisio","year":"1989","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"2","key":"10.1016\/j.bpg.2013.01.001_bib26","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1200\/JCO.1999.17.2.600","article-title":"Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome","volume":"17","author":"Rubin","year":"1999","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bpg.2013.01.001_bib27","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1530\/eje.0.1510107","article-title":"High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours","volume":"151","author":"Welin","year":"2004","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.bpg.2013.01.001_bib28","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1159\/000007693","article-title":"Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors","volume":"60","author":"Faiss","year":"1999","journal-title":"Digestion"},{"issue":"2","key":"10.1016\/j.bpg.2013.01.001_bib29","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000122229","article-title":"Regression of a large malignant gastrinoma on treatment with Sandostatin LAR: a case report","volume":"77","author":"Granberg","year":"2008","journal-title":"Digestion"},{"issue":"28","key":"10.1016\/j.bpg.2013.01.001_bib30","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.bpg.2013.01.001_bib31","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/00001813-199410000-00001","article-title":"Endocrine tumors of the gastrointestinal tract: systemic treatment","volume":"5","author":"Oberg","year":"1994","journal-title":"Anticancer Drugs"},{"issue":"8711","key":"10.1016\/j.bpg.2013.01.001_bib32","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0140-6736(90)91879-F","article-title":"Interferon-induced enhancement of 2',5'-oligoadenylate synthetase in mid-gut carcinoid tumours","volume":"336","author":"Grander","year":"1990","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.bpg.2013.01.001_bib33","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1365-2141.1991.tb08125.x","article-title":"The role of interferons in the management of carcinoid tumours","volume":"79","author":"Oberg","year":"1991","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.bpg.2013.01.001_bib34","first-page":"35","article-title":"The action of interferon alpha on human carcinoid tumours","volume":"3","author":"Oberg","year":"1992","journal-title":"Semin Cancer Biol"},{"issue":"4","key":"10.1016\/j.bpg.2013.01.001_bib35","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0016-5085(00)70143-0","article-title":"Molecular mechanism of interferon alfa-mediated growth inhibition in human neuroendocrine tumor cells","volume":"118","author":"Detjen","year":"2000","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.bpg.2013.01.001_bib36","first-page":"1853","article-title":"Increased local antitumor effects of interleukin 2 liposomes in mice with MCA-106 sarcoma pulmonary metastases","volume":"50","author":"Anderson","year":"1990","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.bpg.2013.01.001_bib37","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00001813-199603000-00005","article-title":"Long-term results of continuous treatment with recombinant interferon-alpha in patients with metastatic carcinoid tumors\u2013an antiangiogenic effect?","volume":"7","author":"Dirix","year":"1996","journal-title":"Anticancer Drugs"},{"issue":"5","key":"10.1016\/j.bpg.2013.01.001_bib38","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/bjc.1992.372","article-title":"Recombinant interferon alpha-2b in patients with metastatic apudomas: effect on tumours and tumour markers","volume":"66","author":"Biesma","year":"1992","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.bpg.2013.01.001_bib39","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3109\/00365529509096329","article-title":"Interferon-alpha 2b, with or without prior hepatic artery embolization: clinical response and survival in mid-gut carcinoid patients. The Norwegian carcinoid study","volume":"30","author":"Jacobsen","year":"1995","journal-title":"Scand J Gastroenterol"},{"issue":"Suppl 2","key":"10.1016\/j.bpg.2013.01.001_bib40","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1093\/annonc\/12.suppl_2.S111","article-title":"Chemotherapy and biotherapy in the treatment of neuroendocrine tumours","volume":"12","author":"Oberg","year":"2001","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.bpg.2013.01.001_bib41","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bpg.2005.02.012","article-title":"Endocrine tumours of the gastrointestinal tract. Biotherapy for metastatic endocrine tumours","volume":"19","author":"Shah","year":"2005","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"8519","key":"10.1016\/j.bpg.2013.01.001_bib42","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S0140-6736(86)91435-2","article-title":"Treatment of malignant endocrine pancreatic tumours with human leucocyte interferon","volume":"2","author":"Eriksson","year":"1986","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.bpg.2013.01.001_bib43","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1200\/JCO.1989.7.7.865","article-title":"Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon","volume":"7","author":"Moertel","year":"1989","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.bpg.2013.01.001_bib44","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3109\/02841869109092413","article-title":"Treatment of gastrointestinal endocrine tumours with interferon-alpha and octreotide","volume":"30","author":"Creutzfeldt","year":"1991","journal-title":"Acta Oncol"},{"issue":"5","key":"10.1016\/j.bpg.2013.01.001_bib45","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/oxfordjournals.annonc.a010633","article-title":"Neuroendocrine gastrointestinal tumours","volume":"7","author":"Oberg","year":"1996","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.bpg.2013.01.001_bib46","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0959-8049(92)90389-J","article-title":"A dose-escalation study of recombinant interferon-alpha in patients with a metastatic carcinoid tumour","volume":"28","author":"Veenhof","year":"1992","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.bpg.2013.01.001_bib47","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1089\/jir.2006.26.8","article-title":"Efficacy and tolerability of pegylated IFN-alpha in patients with neuroendocrine gastroenteropancreatic carcinomas","volume":"26","author":"Pavel","year":"2006","journal-title":"J Interferon Cytokine Res"},{"issue":"4","key":"10.1016\/j.bpg.2013.01.001_bib48","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3109\/02841869109092414","article-title":"Autoimmune phenomena in patients with malignant carcinoid tumors during interferon-alpha treatment","volume":"30","author":"Ronnblom","year":"1991","journal-title":"Acta Oncol"},{"issue":"10","key":"10.1016\/j.bpg.2013.01.001_bib49","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/0959-8049(92)90060-F","article-title":"Octreotide and interferon alfa: a new combination for the treatment of malignant carcinoid tumours","volume":"28A","author":"Tiensuu Janson","year":"1992","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.bpg.2013.01.001_bib50","first-page":"1381","article-title":"Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors","volume":"94","author":"Frank","year":"1999","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.bpg.2013.01.001_bib51","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1385\/MO:19:1:35","article-title":"Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs","volume":"19","author":"Fjallskog","year":"2002","journal-title":"Med Oncol"},{"issue":"2","key":"10.1016\/j.bpg.2013.01.001_bib52","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1530\/acta.0.1260184","article-title":"Dramatic response of a metastatic carcinoid tumour to a combination of interferon and octreotide","volume":"126","author":"Joensuu","year":"1992","journal-title":"Acta Endocrinol (Copenh)"},{"issue":"6","key":"10.1016\/j.bpg.2013.01.001_bib53","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/bjs.4149","article-title":"Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours","volume":"90","author":"Kolby","year":"2003","journal-title":"Br J Surg"},{"issue":"14","key":"10.1016\/j.bpg.2013.01.001_bib54","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1200\/JCO.2003.12.142","volume":"21","author":"Faiss","year":"2003","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.bpg.2013.01.001_bib55","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S1542-3565(05)00481-7","article-title":"Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial","volume":"3","author":"Arnold","year":"2005","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Best Practice & Research Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691813000231?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691813000231?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,2,13]],"date-time":"2022-02-13T13:29:12Z","timestamp":1644758952000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521691813000231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S1521691813000231"],"URL":"https:\/\/doi.org\/10.1016\/j.bpg.2013.01.001","relation":{},"ISSN":["1521-6918"],"issn-type":[{"value":"1521-6918","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biotherapies for GEP-NETs","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpg.2013.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}